Soleus Capital Management L.P. Has $31.95 Million Position in Jasper Therapeutics, Inc. (NASDAQ:JSPR)

Soleus Capital Management L.P. raised its position in Jasper Therapeutics, Inc. (NASDAQ:JSPR) by 11.2% in the 4th quarter, Holdings Channel reports. The firm owned 1,494,420 shares of the company’s stock after buying an additional 150,755 shares during the period. Jasper Therapeutics accounts for approximately 2.0% of Soleus Capital Management L.P.’s investment portfolio, making the stock its 16th biggest holding. Soleus Capital Management L.P. owned about 0.10% of Jasper Therapeutics worth $31,951,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the company. Boxer Capital Management LLC acquired a new position in shares of Jasper Therapeutics in the 4th quarter valued at $7,483,000. Integral Health Asset Management LLC raised its stake in Jasper Therapeutics by 85.7% during the 4th quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company’s stock worth $13,897,000 after buying an additional 300,000 shares during the period. Braidwell LP lifted its holdings in Jasper Therapeutics by 47.9% during the fourth quarter. Braidwell LP now owns 714,658 shares of the company’s stock worth $15,279,000 after acquiring an additional 231,358 shares in the last quarter. Stempoint Capital LP bought a new position in Jasper Therapeutics during the fourth quarter worth about $2,892,000. Finally, T. Rowe Price Investment Management Inc. acquired a new position in Jasper Therapeutics in the fourth quarter valued at about $1,757,000. 79.85% of the stock is currently owned by institutional investors and hedge funds.

Jasper Therapeutics Price Performance

JSPR stock opened at $4.93 on Monday. The stock has a market capitalization of $74.06 million, a P/E ratio of -1.04 and a beta of 2.74. Jasper Therapeutics, Inc. has a fifty-two week low of $3.13 and a fifty-two week high of $26.84. The business has a 50-day moving average of $4.60 and a 200-day moving average of $10.86.

Jasper Therapeutics (NASDAQ:JSPR) last released its earnings results on Monday, May 12th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.24). Equities analysts expect that Jasper Therapeutics, Inc. will post -4.47 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on JSPR shares. HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of Jasper Therapeutics in a report on Tuesday, March 11th. Oppenheimer decreased their price objective on Jasper Therapeutics from $80.00 to $65.00 and set an “outperform” rating for the company in a research report on Thursday. Finally, UBS Group dropped their target price on shares of Jasper Therapeutics from $38.00 to $33.00 and set a “buy” rating on the stock in a report on Tuesday, May 13th. Ten analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $62.22.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.